ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy specialist, has flagged a possible new use of its know-how on the American Association for Cancer Research (AACR) annual assembly in Orlando, Florida, through a poster presentation.

The research demonstrated the potential of mixing two completely different exams, immunofluorescent (IF) staining and HER2 fluorescence in-situ hybridisation (FISH) evaluation, with most cancers cells collected from the blood utilizing ANGLE’s Parsortix system.

The analysis staff efficiently separated most cancers cells from the blood of sufferers with superior breast most cancers utilizing Parsortix.

They then detected a particular protein known as HER2 and recognized completely different cell sorts within the most cancers cells. These findings recommend that combining these methods may assist medical doctors make higher remedy selections for breast most cancers sufferers, as HER2 standing can change over time.

The research is especially necessary as a result of new medication are being developed to focus on low HER2 expression, and the outcomes may considerably broaden the marketplace for HER2 testing.

Using these methods may assist meet an unmet medical want by permitting medical doctors to observe HER2 standing all through a affected person’s illness development.

In a statement, ANGLE founder and chief government, Andrew Newland, mentioned: “The analysis offered showcases the utility of the Parsortix system for accumulating most cancers cells from the blood and analyzing them utilizing a mixed IF and FISH strategy.

“We additionally exhibit profitable detection of HER2 protein overexpression in most cancers cells remoted from superior breast most cancers sufferers, exhibiting the potential for utilizing this system in enhancing affected person remedy plans.

“Given the changing dynamics of the HER2 market in response to the introduction of new drugs targeting low HER2 expression, we believe the proof of concept achieved with this study has significant commercial relevance.”